FBRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FBRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Forte Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $35.31 Mil. Forte Biosciences's Total Assets for the quarter that ended in Dec. 2023 was $38.98 Mil.
The historical rank and industry rank for Forte Biosciences's Equity-to-Asset or its related term are showing as below:
During the past 4 years, the highest Equity to Asset Ratio of Forte Biosciences was 0.96. The lowest was 0.91. And the median was 0.94.
The historical data trend for Forte Biosciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Forte Biosciences Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Equity-to-Asset | 0.96 | 0.96 | 0.92 | 0.91 |
Forte Biosciences Quarterly Data | ||||||||||||||||||
Jun19 | Sep19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.92 | 0.90 | 0.80 | 0.84 | 0.91 |
For the Biotechnology subindustry, Forte Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Forte Biosciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Forte Biosciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Forte Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Equity to Asset (A: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 35.314 | / | 38.98 | |
= |
Forte Biosciences's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as
Equity to Asset (Q: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 35.314 | / | 38.98 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Forte Biosciences (NAS:FBRX) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Forte Biosciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Paul A. Wagner | director, officer: See Remarks | C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121 |
David W Gryska | director | 749 N MARY AVE, SUNNYVALE CA 94085 |
Scott C. Brun | director | C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104 |
Hubert C Chen | officer: See remarks | C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121 |
Stephen K Doberstein | director | 129 ELSIE STREET, SAN FRANCISCO CA 94110 |
Barbara K Finck | director | C/O PROTINE DESIGN LAB, 3858 JACKSON ST, SAN FRANCISCO CA 94118 |
Antony A Riley | officer: Chief Financial Officer | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 94538 |
Thomas E Darcy | director | C/O SCIENCE APPLICATIONS INTL CORP, 10260 CAMPUS POINT DR., SAN DIEGO CA 92121 |
Donald Allen Williams | director | C/O PRYOR CASHMAN LLP, 7 TIMES SQUARE, NEW YORK NY 10036 |
Patricia S Walker | director | 5540 EKWILL ST STE D, SANTA BARBARA CA 93111 |
Lawrence Eichenfield | director | C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502 |
Steven Kornfeld | director | C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502 |
Steven Michael Oliveira | 10 percent owner | 18 FIELDSTONE COURT, NEW CITY NY 10956 |
Fairooz Kabbinavar | officer: SVP Clinical Development | C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121 |
Mark G Foletta | officer: EVP & Chief Financial Officer | AMYLIN PHARMACEUTICALS INC, 9360 TOWNE CENTRE DR, SAN DIEGO CA 92121 |
From GuruFocus
By Business Wire Business Wire • 08-15-2022
By Business Wire Business Wire • 03-31-2023
By Business Wire Business Wire • 06-07-2022
By Business Wire • 09-14-2023
By Business Wire Business Wire • 08-16-2021
By Business Wire Business Wire • 05-04-2021
By Business Wire Business Wire • 09-08-2021
By Business Wire Business Wire • 08-17-2022
By Business Wire Business Wire • 07-01-2021
By Business Wire Business Wire • 06-07-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.